1. Impact of Anti-SARS-CoV-2 Vaccination on Disease Severity and Clinical Outcomes of Individuals Hospitalized for COVID-19 Throughout Successive Pandemic Waves: Data from an Italian Reference Hospital.
- Author
-
Mondi, Annalisa, Mastrorosa, Ilaria, Navarra, Assunta, Cimaglia, Claudia, Pinnetti, Carmela, Mazzotta, Valentina, Agresta, Alessandro, Corpolongo, Angela, Zolezzi, Alberto, Al Moghazi, Samir, Loiacono, Laura, Bocci, Maria Grazia, Matusali, Giulia, D'Annunzio, Alberto, Gallì, Paola, Maggi, Fabrizio, Vairo, Francesco, Girardi, Enrico, and Antinori, Andrea
- Subjects
BOOSTER vaccines ,VACCINE effectiveness ,VACCINATION status ,COVID-19 ,COVID-19 vaccines - Abstract
This is a retrospective observational study including all COVID-19 patients admitted at our Institute throughout three successive pandemic waves, from January 2021 to June 2023. The main in-hospital outcomes (clinical progression [CP], defined as admission to Intensive Care Unit [ICU]/death, and death within 28 days) were compared among participants unvaccinated (NV), fully vaccinated (FV), with one (FV&B1) and two (FV&B2) booster doses. Vaccinated participants were stratified into recently and waned FV/FV&B1/FV&B2, depending on the time elapsed from last dose (≤ and >120 days, respectively). There were 4488 participants: 2224 NV, 674 FV, 1207 FV&B1, and 383 FV&B2. Within 28 days, there were 604 ICU admissions, 396 deaths, and 737 CP. After adjusting for the main confounders, the risk of both in-hospital outcomes was reduced in vaccinated individuals, especially in those who received the booster dose (approximately by 36% for FV and >50% for FV&B1 and FV&B2 compared to NV). Similarly, after restricting the analysis to vaccinated participants only, we observed a risk reduction of approximately 40% for FV&B1 and 50% for FV&B2, compared to FV, regardless of the distance since the last dose. Our data confirm the vaccine's effectiveness in preventing severe COVID-19 and support the efforts to increase the uptake of booster doses, mainly among older and frailer individuals, still at a greater risk of clinical progression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF